$NVO News

Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients

Novo Nordisk Announces Ziltivekimab Did Not Translate Into Major Adverse Cardiovascular Events Risk Reduction During Phase 3 Trial In Patients With Atherosclerotic Cardiovascular Disease

Novo Nordisk: Too Late For A Great Opportunity

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

JYSKE BANK Downgrades Novo Nordisk A (NVO)

Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions

Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal

Novo Nordisk Gets EU Approval for Wegovy Pill for Weight Management

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug

Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children

Novo Nordisk signs pact to assess semaglutide implant

Novo Nordisk Shares Encouraging Long-Term Data From Hemophilia Program

Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals

Novo Nordisk: A Strong Yield And Continued Growth

Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models

Reported June 16, 2026: 'Hacking Group Claims Major Hack Of Novo Nordisk And Attempted $25 Million Extortion' - Reuters News

Novo Nordisk: The Danish Empire Strikes Back

Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy

Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet